About Us
NewAmsterdam Pharma
NewAmsterdam Pharma (Nasdaq:NAMS) is a clinical-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily cholesteryl ester transfer protein (CETP) inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients. Results from NewAmsterdam’s ROSE Phase 2b trial (presented at AHA Scientific Sessions in 2021) included observations that patients receiving obicetrapib 10 mg experienced a median reduction in LDL-C of 51% versus baseline in patients on high-intensity statin therapy (versus a 7% reduction in the placebo arm). Based in the Netherlands, NewAmsterdam was founded in 2019 by the venture capital firm Forbion and John Kastelein, Chief Scientific Officer of NewAmsterdam and closed a $196 million (€160 million) Series A financing in January 2021 led by Forbion, Morningside Ventures, and Ascendant BioCapital. In June 2022, NewAmsterdam entered into an exclusive licensing agreement with the Menarini Group for the commercialization of obicetrapib in Europe, while retaining all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer’s disease.
Management Team and Board
We are led and supported by a world-class team of industry veterans and key opinion leaders, including some of the world’s preeminent cardiometabolic experts.
MANAGEMENT TEAM
Michael Davidson
Chief Executive Officer
Dr. Michael Davidson joined NewAmsterdam Pharma as CEO and Executive Board member as of August 2020. Before joining NewAmsterdam Pharma, Michael was founder and Chief Medical Officer of Corvidia Therapeutics, which sold to Novo Nordisk in July 2020. Michael is a leading expert in the field of lipidology and has been named in The Best Doctors in America for the past 10 years. Michael was the cofounding Chief Medical Officer of Omthera Pharmaceuticals in 2008, which was later acquired by AstraZeneca Pharmaceuticals in 2013 for $443M. He also founded the Chicago Center for Clinical Research, which became the largest investigator site in the United States and was acquired by Pharmaceutical Product Development in 1996. His research background encompasses pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Michael is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Michael received his BA and MS from Northwestern University and his MD from The Ohio State University College of Medicine.
John Kastelein
Chief Scientific Officer
Dr. John Kastelein is founder and CSO of NewAmsterdam Pharma and a member of the Executive Board. John is Emeritus Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam, where he held the office of Strategic Chair of Genetics of Cardiovascular Disease. Professor Kastelein has published over 1,320 research papers in peer-reviewed journals, including Nature Genetics, The Lancet, New England Journal of Medicine, JAMA, and Circulation, with a Hirsch index of 122 in January 2020. His research has been cited more than 74,800 times. Dr. Kastelein is a member of the steering committees of numerous lipid-lowering and cardiovascular intervention trials. His main interest is in the development of novel therapies for cardiovascular diseases and the genetic basis of dyslipidemia. Dr. Kastelein is CEO of the Vascular Research Network, a site maintenance organization comprised of 50 hospitals in the Netherlands, involved in clinical trials for cardiometabolic disease. He is president of the Dutch Atherosclerosis Society and the National Scientific Committee on Familial Hypercholesterolemia and a Fellow of the European Society of Cardiology. In 2010 he was awarded the prestigious Dutch Heart Association award of €1 million and, in 2011, he was awarded the ZonMw Parel for his research in the field of gene therapy. Additionally, Dr. Kastelein is key advisor to a number of biotech and pharmaceutical companies. Dr. Kastelein earned his doctorate in medicine with honors from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver.
Douglas Kling
Chief Operating Officer
Douglas Kling joined NewAmsterdam Pharma in March 2021 as Chief Operating Officer. Previously, he was Senior Vice President of Clinical Operations at Corvidia Therapeutics, which sold to Novo Nordisk in July 2020. At Corvidia, Douglas managed the clinical development of ziltivekimab, an anti-IL6 monoclonal antibody, being developed to treat cardiovascular disease in patients with chronic kidney disease. Douglas is an expert in the development of drugs to treat dyslipidemia and cardiovascular disease. Prior to Corvidia, Douglas was the Senior Vice President of Clinical Development & Project Management at Omthera Pharmaceuticals, which sold to AstraZeneca Pharmaceuticals in 2013. Douglas also worked at the Medicines Company and Reliant Pharmaceuticals, managing the development activities for various drugs in the dyslipidemia and cardiovascular space. Douglas earned a BS from Duke University and an MBA from Rutgers Business School.
Louise Kooij
Chief Accounting Officer
Louise Kooij assumed the role of Chief Accounting Officer at NewAmsterdam Pharma in January 2023 after serving as the company's CFO since May 2020. Before 2016, she worked in different roles with growing responsibility in finance and business. From 2018 to 2020, she was Head of Rare Disease in central and Eastern Europe for Sanofi Genzyme and from 2016 to 2018, she was responsible for leading the European Business Operations team. Prior to that, she served as vice president of Business Control and Analysis (Global Scope) in Boston. Louise has more than 25 years of professional experience, 18 of which she spent with Sanofi Genzyme. Prior to that, she worked as a consultant and auditor at PricewaterhouseCoopers and as a Product Group Accountant at Hagemeyer N.V. Louise was involved with major projects such as the integration of Genzyme into Sanofi, reorganizations, and acquisitions. Louise earned her master’s degree from Nyenrode Business University and her auditing degree from Hogeschool Markus Verbeek.
Jim Jacobson
Chief Legal Officer
Jim Jacobson serves as NewAmsterdam Pharma’s Chief Legal Officer, with responsibility for all legal, contractual, and compliance matters. Jim has more than 25 years of experience in life sciences, biotech and health care law as partner and chair of the life sciences and U.S. Food and Drug Administration practices of two global law firms and as General Counsel to start-up and publicly traded pharmaceutical and medical device companies.
Jim recently served as General Counsel to Q-State Biosciences, Senior Attorney and Chief U.S. Privacy Counsel to Merck KGaA, and General Counsel and Secretary, Chief Compliance Officer, and Chief Privacy Counsel for Aptus Health, a Merck & Co., Inc. affiliate serving pharmaceutical and healthcare provider customers in 80 countries. Before that, Jim was chief counsel to the pharmaceutical and device division of Fresenius Medical Care, one of the world’s largest diversified drug, device, and healthcare services providers.
Earlier in his career, Jim served as judicial clerk on the D.C. Court of Appeals, special counsel to the Clinton White House healthcare task force, and general or special counsel to numerous life sciences and healthcare industry groups, including the Population Health Alliance/Disease Management Association of America; PhRMA, BIO and the Healthcare Distribution Management Association; health insurance and managed care groups including BCBSA, American Association of PPOs, America’s Health Insurance Plans, Health Insurance Association of America, the National Committee for Quality Assurance, and the American Benefits Council; and multiple provider associations including AMA, APA, ACC, AHA and FAHS.
Prior to law school, Jim worked as a research analyst, running clinical trials in psychopharmacology at Mass General Hospital and served as a Peace Corps volunteer in infectious disease and tropical medicine in Thailand. Jim is a graduate of Harvard Law School and Yale College.
Marc Ditmarsch
Chief Development Officer
Marc Ditmarsch joined NewAmsterdam Pharma in January 2020 as Vice President Clinical & Operations. Marc followed his medical training at the Free University in Amsterdam and practiced vascular surgery and accident and emergency medicine for 6 years. He has more than 20 years of professional experience in the pharmaceutical industry where he began as a medical advisor for the atherothrombosis business unit of Sanofi-Synthelabo. In 2004, Marc joined AstraZeneca as a global research physician for the cardiovascular development department and was engaged in the CRESTOR clinical development program. Marc moved to Roche in 2008 where he led the Phase 3b development program for the cholesteryl ester transfer protein inhibitor, including the initiation and execution of the second Cardiovascular Outcomes study. In 2014, Marc joined AstraZeneca as a Global Product Vice President in the Global Medicines Development organization where he was responsible for the BRILINTA clinical development program, which included 6 cardiovascular outcomes trials in more than 80,000 patients. In 2016, he joined AstraZeneca as its Medical Director. During his career in the pharmaceutical industry, Marc has published various articles in peer-reviewed journals.
BJ Jones
Chief Commercial Officer
Before joining NewAmsterdam Pharma, BJ Jones was Chief Commercial Officer of Migraine and Common Disease at Biohaven Pharmaceuticals. In that role, he led his talented team in building an innovative and dominating commercial enterprise that launched Nurtec ODT during the global COVID-19 pandemic. Through strategic innovation, industry-first digital capabilities, and disciplined execution, Biohaven quickly overcame its big pharma competitors and achieved market leadership for Nurtec ODT. In October 2022, Pfizer acquired the number 1 leading migraine franchise for $11.6 billion.
BJ is a seasoned biopharmaceutical executive with 30 years of commercial and launch experience in large pharmaceutical companies and small biotech firms. His commercial experience includes mass market product launches for notable brands such as Nurtec ODT, Farxiga, Pradaxa, BiDil, and Abilify. Throughout his career, BJ has held leadership roles in marketing, sales, operations, and business development at Takeda, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, and NitroMed.
BJ is a graduate of the United States Air Force Academy and attained the rank of Major through his active duty and reserve service. He has a Master of Business Administration from Stanford Graduate School of Business and a Master of Science degree in industrial engineering from Texas A&M University.
Ian Somaiya
Chief Financial Officer
Ian Somaiya joined NewAmsterdam as Chief Financial Officer in October 2023. Mr. Somaiya has over 25 years of experience in finance and biotechnology. Most recently, he was Chief Financial and Business Officer at Elucida Oncology, where he was responsible for fund raising and overall corporate strategy. At TCR2 Therapeutics, he successfully navigated the company through its IPO and two follow-on financings, raising more than $350 million. During his nearly four years at TCR2, he led the company’s finance and public company reporting as well as business development and investor relations functions.
Prior to joining TCR2, Mr. Somaiya spent over 20 years on Wall Street where he conducted extensive research on more than 100 biotechnology companies across diverse therapeutic areas, technology platforms and stages of development. He was Managing Director and Head of Biotechnology Research at BMO Capital Markets, and served as a Managing Director and Equity Analyst at Nomura Securities Co. Ltd., Piper Jaffray Companies and Thomas Weisel Partners Group, Inc. He launched his Wall Street career as a research analyst at Morgan Stanley and Prudential Securities and was recognized as the "Best on the Street" by The Wall Street Journal for his coverage on biotechnology in 2006, 2007 and 2009. Mr. Somaiya received a Bachelor of Arts degree in Biology and Neuroscience from New York University.
Sheng Cui
Chief Manufacturing Officer
Sheng Cui, PhD, joined NewAmsterdam Pharma in April 2021 as Vice President and Head of Chemistry Manufacturing and Controls (CMC). Previously, he was Vice President of CMC at Boston Pharmaceuticals where he managed phase-appropriate CMC development strategy and execution for a diversified portfolio. Prior to that, Dr. Cui served as a Scientific Director in process development organization at Amgen, where he took on roles of increasing responsibility for advancing synthetic drug candidates, spanning the life cycle from preclinical to commercialization with leadership roles on numerous investigational new drug applications, new drug applications, and major post-approval variations, including recently launched products, such as Parsabiv and Kyprolis. Dr. Cui’s ability and commitment as a leader in successfully developing and implementing green chemistry technologies for the Parsabiv manufacturing process was recognized by the US Environmental Protection Agency with the prestigious 2017 Green Chemistry Challenge Award. Dr. Cui has been actively involved in the external scientific community through publications, patents, and presentations and received the Industrial Young Investigator Award from the American Chemical Society. Dr. Cui received his postdoctoral training at Harvard University, PhD in organic chemistry from Case Western Reserve University and BS in chemistry from Nankai University.
Juliette Audet
Chief Business Officer
Juliette Audet joined NewAmsterdam Pharma as CBO in April 2024. She was most recently a Partner at Forbion, a life science VC fund, where she was part of the team that built NewAmsterdam Pharma and served as one of its Board Member from inception to her transition to the executive team. Before that, Juliette was a Principal at the Novartis Venture Fund, based in Cambridge, Massachusetts, and prior to this position, she was a Senior Manager of Strategy at Novartis AG. Juliette spent the first part of her career in management consulting at McKinsey and Company focusing on pharma and biotech, based out of its Swiss and New York offices. Juliette graduated with distinction from Harvard Business School in 2015 with an MBA and received her MSc in physics, graduating summa cum laude from Lausanne, Swiss Federal Institute of Technology in 2010.
Bob Rambo
Executive Vice President, Marketing and Medical Affairs
Bob Rambo joined NewAmsterdam Pharma as Executive Vice President of Marketing and Medical Affairs in January 2023 and supported NewAmsterdam’s initial commercial and medical affairs efforts as a consultant since November 2021.
Prior to leading a lucrative consulting business, Bob had a successful 32-year career at Merck in multiple marketing, medical, and sales leadership roles launching brands that routinely exceeded multi-billion dollar targets. Bob’s marketing leadership helped propel Merck’s Hepatitis C franchise to $1.7 billion annually in two years, making it the second most successful launch at Merck. Through various medical affairs and marketing leadership roles, Bob’s contributions helped to drive the U.S. ezetimibe franchise (Zetia and Vytorin) to more than $4 billion in peak annual sales. Bob has been recognized throughout his career for consistently exceeding sales objectives while empowering diverse, high-performing teams. Bob is a therapeutic expert in lipids and cardiology, having spent a significant portion of his career in the cholesterol market across Merck’s portfolio of statins, ezetimibe products, and cholesteryl ester transfer protein inhibitors.
Bob has an MBA from the Fox School of Business and a BS in microbiology from Penn State University.
Annie Neild
Executive Vice President and Head of Global Regulatory Affairs
Annie Neild joined NewAmsterdam Pharma in March 2021 as Vice President of Regulatory Affairs. She has 15 years of regulatory experience in the pharmaceutical industry, working across diverse therapeutic areas with small molecules, peptide therapeutics, and biologics. Annie completed her doctoral work at Yale University, where she studied the interactions between intracellular pathogens and the host immune response. After concluding her postdoctoral studies at the Rockefeller University, Annie joined the pharmaceutical industry in 2006. In 2010, she joined the biometrics group at Ironwood Pharmaceuticals and was part of the Linzess new drug application team before she moved to Regulatory Affairs, where she led the development and submission of investigational new drug applications for Ironwood’s soluble guanylate cyclase stimulators for cardiovascular and renal indications. She continued her work on these compounds when Cyclerion separated from Ironwood in 2019. Annie joined the Regulatory Affairs team at Corvidia Therapeutics in 2020, where she facilitated the transition of Corvidia’s asset ziltivekimab to Novo Nordisk following the acquisition in July 2020.
Matthew Philippe
Executive Vice President and Head of Investor Relations
Matthew (Matt) Philippe joined NewAmsterdam Pharma as Executive Vice President and Head of Investor Relations in April 2023 with nearly 20 years of healthcare investing and corporate finance experience. From 2019 through 2023, Matt was a portfolio manager at Schonfeld Strategic Advisors, running a $350 million fundamental healthcare portfolio. Between 2015 and 2019, he was an Equities Analyst leading the global healthcare initiative at Karst Peak Capital, a US $1+ billion long-short equity hedge fund based in Hong Kong. From 2014-2015, Matt was Vice President of medical supply and device research at Deutsche Bank in New York. Prior to that, he was an Analyst at Avet Capital Management, a long-short equity fund focused exclusively on the healthcare sector. In addition, he worked at Numoda Capital Innovations, a private equity and venture capital firm investing in healthcare services, biotechnology and device companies. Matt began his healthcare corporate finance career with the Global Healthcare Group at C.E. Unterberg Towbin, which was acquired by Collins Stewart during his tenure.
He received his MBA from Columbia Business School in 2013 and received his BS in biology, BS in finance, BA in spanish and minors in chemistry and biomedical sciences from Colorado State University, where he graduated as a University Honors Scholar in 2005.
Chris Deluzio
Executive Vice President, Enterprise Operations
Chris Deluzio joined NewAmsterdam Pharma in September of 2023 as the Executive Vice President, Enterprise Operations. Chris has over two decades of experience in the pharmaceutical industry, working across primary care, hospital, and specialty sales in sales leadership, market access, and commercial operations. He’s covered a variety of therapeutic areas at “big pharma” companies including BMS, AstraZeneca, Boehringer-Ingelheim, and Takeda, as well as four “start-up” pharma organizations.
Chris has broad commercial experience in building organizations as well as leading integrations amongst small and large pharma companies. Most recently, Chris was the Commercial Integration Lead between Pfizer and Biohaven after Pfizer’s acquisition of Biohaven in the fall of 2022. Prior to that, he was responsible for Sales and Commercial Operations at Biohaven. In that role, Chris led an ~800-person sales organization as well as a virtual engagement customer facing team. Chris also was responsible for all commercial operations supporting Sales, Marketing, and Market Access.
Chris did his undergraduate studies at Rutgers University and graduate studies at the University of Pennsylvania.
NON-EXECUTIVE BOARD
Will is the Chair and Chief Executive Officer of Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on serious and rare diseases. He joined Insmed in 2012 as President and CEO and as a member of the board of directors, and became chair of the board in 2018. Will is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), and previously spent more than 10 years working in investment banking in the U.S. and Europe. He also previously worked for the U.S. government.
Will holds a Bachelor of Arts degree cum laude from Oberlin College as well as a Master of Business Administration and a Juris Doctor with Honors from Case Western Reserve University. Will is a member of the Board of Trustees of Case Western Reserve University and a member of the Board of Trustees of BioNJ, the life sciences association for New Jersey.
William H. Lewis, J.D., M.B.A. - Chair
James N. Topper
James (Jamie) Topper is a Managing Partner of Frazier Healthcare Partners' Life Sciences team. He joined Frazier in 2003 and opened Frazier's Menlo Park office that year. Throughout his 16 years as a Managing Partner, Jamie has invested across more than 35 companies encompassing a broad spectrum of life science and biopharmaceutical companies. Jamie has led many of Frazier's successful life sciences investments including Acerta Pharma BV (sold to AstraZeneca), Amunix Pharmaceuticals (sold to Sanofi), Calistoga Pharmaceuticals (co-founder, sold to Gilead Sciences). Mavupharma (sold to AbbVie), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company). Alnara (sold to Lilly), Portola (co-founder, Nasdaq: PTLA), CoTherix (sold to Actelion), and Threshold (Nasdaq: THLD). He currently represents Frazier on the boards of Alpine Immune Sciences (Nasdaq: ALPN), AnaptysBio (Nasdaq: ANAB), Lassen Therapeutics, NewAmsterdam Pharma (Nasdaq: NAMS), Phathom Pharmaceuticals (Nasdaq: PHAT), and Seraxis. In addition, Jamie is a board observer for Alcresta Therapeutics.
He previously served as Chairman and Chief Executive Officer of Frazier-sponsored special purpose acquisition company Frazier Lifesciences Acquisition Corporation. Prior to joining Frazier, Jamie was the head of cardiovascular research and development at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Before the merger of COR and Millennium, he served as the Vice President of Biology at COR and was responsible for all research activities. He served on the medical school faculties at Stanford and Harvard Medical School prior to joining COR.
Jamie received his MD and PhD in biophysics from Stanford and holds a BS from the University of Michigan. He did his postgraduate training in internal medicine and cardiovascular disease at the Brigham and Women's Hospital in Boston. He has authored more than 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford. In 2011 and 2016, Jamie was named to the Midas List of leading venture capitalists and in 2013 was recognized by Forbes as one of the top 10 healthcare investors.
Nicholas Downing
Dr. Downing joined Bain Capital Life Sciences in 2018 as a Managing Director. Prior to joining Bain Capital, Dr. Downing was a resident physician at the Brigham and Women's Hospital in Boston, where he cared for patients on the inpatient medical service and in the outpatient clinic. Throughout his medical career Dr. Downing has been an active health policy researcher and is the author of more than 40 articles in peer-reviewed scientific literature. Prior to his medical career, Dr. Downing was a consultant at McKinsey and Company where he worked with clients in the pharmaceutical, hospital, and financial services industries on a wide range of strategic problems. Dr. Downing graduated from Harvard college magna cum laude with a degree in chemistry. He received an MD cum laude from Yale University School of Medicine.
Sander Slootweg
Sander Slootweg is Managing Partner at Forbion. He currently serves on the boards of Forbion's portfolio companies Replimune, NorthSea (Chair), Azafaros, Xention, and Oxyrane. Sander was responsible for several substantial exits, including Forbion's major position in Argenx, which was sold in 2018, Amgen’s acquisition of NewAmsterdam Pharma's predecessor Dezima Pharma in 2015 for $1.55 billion, and Amgen’s acquisition of Biovex in 2011 for $1 billion. In recent years Sander has also served on the boards of Pulmagen Fovea (sold to Sanofi in 2009), uniQue (IPO on Nasdaq in 2014), and Argenta (sold to Galapagos in 2010). Alantos Pharmaceuticals, Inc. (sold to Amgen in 2007), Impella (sold to Abiomed in 2005), Pieris (IPO on Nasdaq in 2015) and has acted as the Chairman of the Board of AMT (IPO on Euronext in 2007).
Before co-founding Forbion, he was an Investment Director at ABN AMRO Capital Life Sciences. His other activities at ABN AMRO included buy-out and growth equities at ABN AMRO Capital, Equity Capital Markets Syndications (headquartered in Amsterdam) and Financial Institutions Relationship Management Latin America, with its regional office Miami.
Sander holds degrees in business and financial economics from the Free University of Amsterdam and Business Nijenrode University in the Netherlands.
Lou Lange
Dr. Lange has 22 years of experience in academic medicine at Harvard and Washington University, where he served as Chief of Cardiology and Professor of Medicine at Jewish Hospital from 1985 to 1992, where he was one of the first academicians in molecular cardiology. He founded CV Therapeutics based on this broad field and served as Chairman, CEO, and Chief Scientific Officer. Dr. Lange is a member of the Board of Trustees at the University of Rochester, and a member of BIO Board of Directors. Dr. Lange has been on numerous other public and private boards in both the non-profit and for-profit arena. Dr. Lange has a bachelor’s degree from the University of Rochester, and earned his MD and PhD in biological chemistry from Harvard University.
John Smither
John Smither brings extensive financial and operating management experience to NewAmsterdam Pharma's Board of Directors. Most recently, he served as the Chief Financial Officer (CFO) at Arcutis Biotherapeutics, where he was responsible for all financial aspects, including leading the company’s successful initial public offering and two capital raises. Prior to joining Arcutis, Mr. Smither acted as CFO for Sienna Biopharmaceuticals and as interim CFO for Kite Pharma during its integration with Gilead. He has also served as CFO of Unity Biotechnology and Kythera Biopharmaceuticals. In his various CFO positions, John oversaw multiple private and public financing rounds, including Kythera’s initial public offering and initial IPO preparations at Sienna. Additionally, John has previously served on the boards of several biopharmaceutical companies including Achaogen, Inc. and Dompé Biotec, SpA. He currently serves as Director at eFFECTOR Therapeutics and Applied Molecular Transport.
Earlier in his career, Mr. Smither held various positions at Amgen, where he served as Vice President of Finance and Administration for Amgen's European Division and was responsible for financial operations in 28 European countries. Prior to that, John served as Head of Internal Audit and served as executive director of Corporate Accounting following his time in Europe. Prior to joining Amgen, he served as an Audit Partner at Ernst & Young LLP, a public accounting firm and served as CFO of several early-stage companies.
He holds a Bachelor of Science in business administration from California State University, Los Angeles. Mr. Smither is a Certified Public Accountant (inactive) and a member of the American Institute of Certified Public Accountants and the California Society of Certified Public Accountants.
Janneke van der Kamp
As Chief Commercial Officer of Grünenthal, Janneke van der Kamp brings extensive commercial experience to NewAmsterdam Pharma's Board of Directors. In her current position, Janneke oversees the development and implementation of global commercial strategies for the pain medication focused Grünenthal portfolio. Janneke has more than 20 years of experience in the pharmaceutical industry, including roles as Head of Global Neurosciences Franchise, Global Head of Product and Portfolio Strategy for the entire Novartis Pharma portfolio and Head of Europe for Novartis Pharma, successfully leading an organization with approximately 8,000 associates and $9 billion turnover. At Novartis, Janneke spearheaded cardiovascular disease medicine franchises, including Entresto for heart failure and Inclisiran for Atherosclerotic cardiovascular disease.
Janneke is also well known for deep expertise in launching and growing key brands in a wide array of other disease states, including immunology, dermatology, neuroscience, ophthalmology, and respiratory disease. She holds a master’s in chemistry from Utrecht University, started her career in Strategy Consulting, and then received her MBA from INSEAD.
EXECUTIVE BOARD
-
Michael Davidson
Chief Executive Officer
-
John Kastelein
Chief Scientific Officer
BOARD OBSERVERS
Wouter Joustra (Forbion)
Wouter Joustra is a General Partner at Forbion and joined the company in 2019 to co-launch Forbion’s Growth Opportunities Fund. Previously, Wouter was a Senior Trader of Life Sciences at Kempen, one of the leading European investment banks focused on Life Sciences and Healthcare. In this role, Wouter ran Kempen’s life sciences portfolio and was involved in deal structuring and equity capital market transactions. Wouter also served as an Executive Board member of Kempen’s life sciences franchise. As part of his portfolio at Forbion, Wouter currently serves as a board member at Gyroscope Therapeutics.
CLINICAL ADVISORY BOARD
Christie Ballantyne
Professor & Chief of Cardiology and Cardiovascular Research, Baylor College of Medicine
Maciej Banach
Head of the Department of Preventive Cardiology and Lipidology, Medical University in Lodz, Poland; Secretary, European Atherosclerosis Society; President, Polish Lipid Association
Alberico Catapano
Full Professor of Pharmacology & Director of the Center of Epidemiology and Preventive Pharmacology, University of Milan; Director of the Laboratory of Lipoproteins, Immunity and Atherosclerosis and the Center for the Study of Atherosclerosis, Bassini Hospital
Brian Ference
Professor and Director of Research, Translational Therapeutics; Executive Director of the Center for Naturally Randomized Trials, University of Cambridge
Ulrich Laufs
Professor of Cardiology, Leipzig University of Germany; Chairman of Cardiology, Leipzig University Hospital
Roxana Mehran
Professor of Medicine & Director of Interventional Cardiovascular Research and Clinical Trials, Cardiovascular Institute at Mount Sinai School of Medicine
Ann Marie Navar
Associate Professor in the Departments of Internal Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center
Stephen Nicholls
Director of the Monash Cardiovascular Research Center, Monash University
Steven E. Nissen
Chairman of the Heart and Vascular Institute, Cleveland Clinic; Professor of Medicine, Lerner College of Medicine
Kosh Ray
Faculty of Medicine at the School of Public Health, Imperial College London